- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35.
- Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398405.
- Van den Bosch F, Krulthof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy : effect of TNF-a blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
- Sheldon DG, Sawchuk LL, Kozarek RA Thielby RC. Twenty cases of peristomal pyoderma gangrenosum. Arch Surg 2000; 135:564-8.
- Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284:1546-8.
- Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 2001;137:930-3.
- Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharm Ther 2001;15:1639-46.
- MacDonald TT, Hutching s P, Choy MY, Murch S, Cooke A. Tumour-necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
- Murch SH, Braegger SP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
- Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-á blockade in rheumatoid arthritis. Clin Exp Immunol 1995;101:207-12.
- Cope AP, Londei M, Chu Nr, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/ CD3 complex : reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
- Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TCl (cytotoxic lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-9.
- D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopie and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-34.
Scandinavian Journal of Gastroenterology
Volume 37, 2002 - Issue 9